Introduction
============

Pulmonary sarcomatoid carcinoma (PSC) is a rare type of non-small cell lung cancer (NSCLC) composed of poorly differentiated cells and sarcoma or sarcomatoid components (spindle and/or giant cells) ([@b1-ol-0-0-11472]). PSC accounts for 0.3--1.0% of all lung cancer cases ([@b2-ol-0-0-11472],[@b3-ol-0-0-11472]). Systematic reports of PSC are uncommon due to the inherent rarity of the disease. Therefore, decisions regarding treatment strategies are based on clinicopathological descriptions of small case series or single case reports ([@b4-ol-0-0-11472],[@b5-ol-0-0-11472]).

Previously, Yendamuri *et al* ([@b2-ol-0-0-11472]) identified 1,921 patients with PSC from the Surveillance, Epidemiology and End Results (SEER) database (1973--2008). Another study conducted by Steuer *et al* ([@b6-ol-0-0-11472]) identified 7,965 patients with PSC from the National Cancer Database (1998--2011). The aforementioned studies confirmed that PSC is a relatively rare histological type of lung cancer with lower overall survival (OS) rates compared with other NSCLC types. Complete resection is an essential treatment in the absence of metastasis in patients with PSC. However, the role of adjuvant chemotherapy remains unclear ([@b7-ol-0-0-11472],[@b8-ol-0-0-11472]). To the best of our knowledge, few studies ([@b6-ol-0-0-11472],[@b9-ol-0-0-11472]) have focused on the effect of radiotherapy on the survival of patients with PSC. An unfavorable prognosis is anticipated due to the pathological features of poorly differentiated tumors. The different pathological types of PSC are also poorly studied.

To date, the PSC treatment strategy that is selected depends on the disease stage ([@b10-ol-0-0-11472]). Thus, similar to other types of NSCLC, clinicians need to pay attention to early-stage resectable PSC. Clinicians must achieve a rapid preoperative diagnosis and minimize the delay before surgery to avoid tumor progression. Radical surgical resection ([@b11-ol-0-0-11472]) is recommended for operable patients and also facilitates accurate diagnosis. Patients with PSC significantly benefit from cancer-directed surgery ([@b12-ol-0-0-11472],[@b13-ol-0-0-11472]).

In the present study, five specific types of sarcomatoid carcinoma were used to address the aforementioned unresolved questions using the World Health Organization (WHO) classification system (2015). The five specific types of sarcomatoid carcinoma studied were pure spindle cell, pure giant cell, carcinosarcoma, pulmonary blastoma and pleomorphic, which includes tumors with spindle and giant cells ([@b14-ol-0-0-11472]). The Surveillance, Epidemiology, and End Results (SEER) program is supported by the National Cancer Institute. The program collects a variety of details, including cancer incidence and survival, from 18 population-based cancer registries throughout the USA, covering 27.8% of the USA population ([@b15-ol-0-0-11472]). A retrospective analysis of patients with PSC registered in the SEER database between 1988 and 2016 was performed to determine the prognostic impact of clinicopathological characteristics and treatment modalities.

Materials and methods
=====================

### Patients

All patients with histologically confirmed PSC between 1988 and 2016 were extracted from the SEER database (<https://seer.cancer.gov/>) using SEER\*Stat 8.3.5 software (<https://seer.cancer.gov/seerstat/>). The age range of the patients was 18--94 years (mean age, 65.9 years), and there was a slightly higher percentage of males (59.9%; n=1,032) compared with females (40.1%; n=691). Patients with primary PSC (n=1,723) as their only primary cancer were included. The inclusion criteria were: i) Pathologically confirmed PSC between 1988 and 2016; and ii) the site recode ICD-O-3/WHO 2008 definition (International Classification of Diseases for Oncology, Third Edition) ([@b16-ol-0-0-11472]) was 'Lung and Bronchus'. The exclusion criteria included: i) Multiple primary tumors; ii) no prognostic data; and iii) lack of clinicopathological data.

The demographic features and clinicopathological characteristics of these patients were collected and are presented in [Table I](#tI-ol-0-0-11472){ref-type="table"}. Of the 1,723 patients, 776 underwent surgery. Of the 776 patients, 264 had stage I, 145 had stage II, 211 had stage III, 44 had stage IV PSC and 112 had no data regarding stage. The OS time was the measured primary outcome and was defined as the interval from diagnosis to death from any cause or the last follow-up in the SEER database. Tumor-Node-Metastasis (TNM) staging was performed according to the American Joint Committee on Cancer (AJCC) 3rd Edition (1988--2003) (<https://seer.cancer.gov/seerstat/variables/seer/ajcc-stage/3rd.html>), 6th Edition (2004--2009) and 7th Edition (2010--2016) (<https://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx>). Several variables, such as age at diagnosis, sex, laterality, primary site, pathological type, differentiation, TNM and the use of surgery and radiotherapy were collected.

### Statistical analysis

The optimal cut-off value of age and tumor size for OS rate was determined using X-tile (Yale School of Medicine) software (version 3.6.1). The Kaplan-Meier method was used to generate survival curves. Differences in OS rate stratified by each covariate were analyzed by the log-rank test. Univariate and multivariate cox proportional hazard models were used to assess the associations between each covariate and OS rate. The results were presented as hazard ratios and 95% confidence intervals (CIs). Propensity matching was performed in R v.3.5.2 (<https://www.r-project.org/>) using the nearest neighbor matching and a caliper width of 0.02. A nomogram was developed and modeled using the rms package of R software (version 5.1--4; <http://cran.r-project.org/web/packages/rms/index.html>). Statistical analysis was conducted using SPSS 20 (IBM Corp.). P\<0.05 (two sided) was considered to indicate a statistically significant difference.

Results
=======

### Baseline characteristics of patients with PSC

A total of 3,897 patients initially diagnosed with PSC between 1975 and 2016 were identified in the SEER database. Of these, 1,723 eligible patients were included in the study. The study workflow and selection process are presented in [Fig. 1](#f1-ol-0-0-11472){ref-type="fig"}. Patient demographic and clinicopathological characteristics are presented in [Table I](#tI-ol-0-0-11472){ref-type="table"}.

### Survival analyses

The median survival time was 8 months (range, 0--337 months). The 1-, 2-, 3- and 5-year survival rates were 38.6, 26.3, 22.1 and 18.1%, respectively. The optimal cut-off values of age and tumor size at diagnosis were 76.0 years and 56 mm, respectively, as set by X-tile analysis. The OS rates of patients with clinicopathological and demographic characteristics, such as male (P=0.004; [Fig. 2B](#f2-ol-0-0-11472){ref-type="fig"}), aged ≥76 years (P\<0.0001; [Fig. 2A](#f2-ol-0-0-11472){ref-type="fig"}), unmarried (P=0.0123; [Fig. 2D](#f2-ol-0-0-11472){ref-type="fig"}), poor tumor-differentiated grade (P\<0.0001; [Fig. 3E](#f3-ol-0-0-11472){ref-type="fig"}) and large tumor size ≥56 mm (P\<0.0001; [Fig. 3B](#f3-ol-0-0-11472){ref-type="fig"}), were significantly worse compared with other patients. The analyses stratified by stage demonstrated that stage I patients with PSC demonstrated improved OS outcomes compared with stage II--IV patients (P\<0.0001; [Fig. 3A](#f3-ol-0-0-11472){ref-type="fig"}). The 5-year OS rates for patients with PSC were as follows: Stage I, 40.3; stage II, 23.8; stage III, 16.0 and stage IV, 2.3%. Patients with pulmonary blastoma demonstrated improved OS rates compared with other pathological types (P\<0.0001; [Fig. 3F](#f3-ol-0-0-11472){ref-type="fig"}). Other factors, including laterality ([Fig. 3C](#f3-ol-0-0-11472){ref-type="fig"}), ethnicity ([Fig. 2C](#f2-ol-0-0-11472){ref-type="fig"}) and primary site ([Fig. 3D](#f3-ol-0-0-11472){ref-type="fig"}), did not significantly affect OS rate.

### Surgery and radiotherapy effects on OS of patients with PSC

Patients with a history of surgical treatment at the primary site exhibited a significantly improved OS compared with those that received no specific treatment (median survival, 21.0 vs. 4.0 months; P\<0.001; [Fig. 4A](#f4-ol-0-0-11472){ref-type="fig"}). The 2-year OS rate of the 'only radiotherapy' group was significantly higher compared with the 'no specific treatment' group (9.1 vs. 5.4%; P\<0.001; [Fig. 4B](#f4-ol-0-0-11472){ref-type="fig"}). The analyses stratified by stage demonstrated that radiotherapy significantly improved the OS rate in stage I--III patients with PSC without surgical resection (P\<0.001; [Fig. 5A](#f5-ol-0-0-11472){ref-type="fig"}) and stage IV patients with PSC without surgical resection (P=0.1764, [Fig. 5B](#f5-ol-0-0-11472){ref-type="fig"}). Subgroup analyses for AJCC 3rd, 6th and 7th groups demonstrated that similar trends still existed (all P\<0.05; [Fig. S1](#SD1-ol-0-0-11472){ref-type="supplementary-material"}).

Furthermore, the patients that received only surgery demonstrated improved progress compared with those who received surgery combined with radiotherapy (P\<0.001; [Fig. 6A](#f6-ol-0-0-11472){ref-type="fig"}). After matching the propensity scores, the 'surgery plus radiotherapy group' consisted of 156 and 'only surgery group' of 247 patients with PSC (1:2). However, no significant differences in the prognosis were found between the two subgroups (P=0.052; [Fig. 6B](#f6-ol-0-0-11472){ref-type="fig"}).

### Independent prognostic risk factors that affect OS of patients with PSC

In the present study, univariate and multivariate Cox proportional hazard analyses of the variables potentially influencing OS of patients with PSC were investigated. Univariate analysis revealed that older age, male, unmarried, giant cell carcinoma, worse pathological grade, larger tumor size, later TNM stages and no special treatments were associated with a worse OS rate (all P\<0.05; [Table II](#tII-ol-0-0-11472){ref-type="table"}). Using multivariate analysis, all factors except for differentiation (P=0.190, [Table II](#tII-ol-0-0-11472){ref-type="table"}) were still identified as independent risk factors of prognosis for patients with PSC.

### Predicting OS of patients with PSC using a nonogram model

Age and tumor size were stratified using X-tile software. This revealed that the optimal cut-off points for age for predicting progression were 63 and 79 years old. The optimal cut-off points for tumor size for predicting progression were 50 and 75 mm. Subsequently, patients with PSC were divided into three groups according to these optimal cut-off values. These groups included the following: i) Young group (\<63 years); ii) middle aged group (63-79 years); and iii) old group (\>79 years). In addition patients were grouped according to tumor size: i) \<50 mm; ii) 50--75 mm; and iii) \>75 mm. Significant differences were observed between the Kaplan-Meier curves for OS among the three age and tumor size groups (all P\<0.05; data not shown).

Next, a nomogram model was established to predict the survival of patients with PSC. This model incorporated all the independent prognostic factors found using multivariate analysis ([Fig. 7](#f7-ol-0-0-11472){ref-type="fig"}). In the model, a high score was associated with good prognosis. TNM, treatment modality and age contributed the most to prognosis, followed by pathological type and tumor size. The C-index of the nomogram model for OS prediction was 0.75 (95% CI, 0.74--0.76).

Discussion
==========

The present study summarized the clinical characteristics of patients with PSC and identified several survival factors using data from the SEER database from 1975--2016. In the present study, the median survival of patients with PSC was 8 months, and the 1-year survival rate was 38.6%. The 2-, 3-, and 5-year survival rates were 26.3, 22.1 and 18.1%, respectively. Compared with previous studies ([@b6-ol-0-0-11472],[@b17-ol-0-0-11472],[@b18-ol-0-0-11472]), the present study demonstrated that the survival rate was slightly low with a median survival range of 11--19 months, a 1-year survival rate of 32--71% and a 5-year survival rate of 17--29%. This outcome may be attributable to patients enrolled in previous studies that had surgical resection ([@b8-ol-0-0-11472],[@b12-ol-0-0-11472],[@b13-ol-0-0-11472],[@b17-ol-0-0-11472]). One of these studies ([@b13-ol-0-0-11472]) also had a high proportion of patients with early-stage PSC.

Morphologically, PSC is generally characterized by a high degree of variability and heterogeneity of the tumor ([@b19-ol-0-0-11472],[@b20-ol-0-0-11472]). The present study also revealed that the most common histological subtype was giant cell carcinoma, followed by spindle cell carcinoma, pleomorphic carcinoma and carcinosarcoma. Previous reports demonstrated that pleomorphic carcinoma was a common histological subtype ([@b1-ol-0-0-11472],[@b3-ol-0-0-11472],[@b21-ol-0-0-11472],[@b22-ol-0-0-11472]). The WHO 2015 lung cancer classification ([@b14-ol-0-0-11472]) reported that the least common subtype of PSC is pulmonary blastoma ([@b23-ol-0-0-11472]), which is consistent with the findings of the present study. Previous studies have identified that pulmonary blastoma counts accounts for 3.02% of all PSC cases ([@b3-ol-0-0-11472],[@b6-ol-0-0-11472]). Most types of sarcomatoid carcinoma are poorly differentiated, pleomorphic-like carcinoma ([@b7-ol-0-0-11472],[@b24-ol-0-0-11472]), spindle cell carcinoma ([@b25-ol-0-0-11472]), giant cell carcinoma ([@b26-ol-0-0-11472]) and carcinosarcoma ([@b21-ol-0-0-11472],[@b25-ol-0-0-11472]). Pulmonary blastoma is a subtype of a well-differentiated biphasic tumor and mainly composed of a primitive epithelial component ([@b21-ol-0-0-11472]). The present results demonstrated that 51.8% of pulmonary blastoma cases were well differentiated or moderately differentiated. Poorly differentiated or undifferentiated occurred in a majority of other types of PSC (93.6--99.7%). The present study also demonstrated that patients with pulmonary blastoma exhibited improved survival, with a 60.2% 5-year OS rate compared with 12.2--23.7% for the other types of sarcamatoid carcinoma. Therefore, pulmonary blastoma is a well-differentiated malignancy and has a favorable survival outcome.

In the present study, 776 of the 1,723 patients underwent surgery. Of the 776 patients who underwent surgery, 67.2% had stage I--II PSC. Meanwhile, of the 776 patients who underwent surgery, 255 (32.8%) had stage III/IV PSC. PSC has been reported to be associated with high rates of recurrence and low OS rates even after complete surgical resection ([@b6-ol-0-0-11472],[@b11-ol-0-0-11472],[@b17-ol-0-0-11472]). Aforementioned studies ([@b13-ol-0-0-11472],[@b27-ol-0-0-11472]) also investigated the effects of neoadjuvant chemotherapy and radiotherapy on the OS rate of patients with PSC. In patients with high-risk stages IB, II and IIIA NSCLC, platinum-based combination regimens are the mainstream treatment strategies ([@b28-ol-0-0-11472]). A beneficial effect of chemotherapy on the OS rate of patients with PSC can be difficult to detect due to the low incidence of this disease ([@b3-ol-0-0-11472]). Furthermore, to the best of our knowledge, studies investigating the effects of chemotherapy on the OS rate of patients with PSC are uncommon. The present study considered multimodal treatment; however, could not assess the potential survival impact of chemotherapy among patients with PSC due to the lack of specific information regarding chemotherapy in the SEER database.

The role of radiotherapy in patients with PSC is poorly defined ([@b29-ol-0-0-11472]). Radiotherapy has been used alone and in combination with chemotherapy in patients with unresectable disease or in an adjuvant setting for those with high rates of recurrence ([@b30-ol-0-0-11472]). Clinically, radiotherapy is always reserved for patients with rare types of lung cancer ([@b31-ol-0-0-11472],[@b32-ol-0-0-11472]). To date, few studies have focused on the value of radiotherapy in PSC. Several prospective randomized studies have failed to demonstrate advantages in delivering radiotherapy in patients with PSC ([@b24-ol-0-0-11472]). In the present study, radiotherapy has an important impact on the survival of patients with PSC stratified by stage, particularly stages I--III. However, patients with PSC who had undergone surgery combined with radiotherapy had a worse OS compared with those who only received surgery. Propensity score matching was also used to reduce bias in the present study. After matching the propensity scores, the prognostic analysis did not significantly differ between the two groups. Chaft *et al* ([@b3-ol-0-0-11472]) conducted a prospective study on patients with PSC and demonstrated patients that underwent surgery plus adjuvant therapy did not have a statistically significant survival benefit compared with those who received surgery alone. This finding is similar to the results obtained by the current study.

The present study had several limitations. First, the study was conducted in a retrospective manner, which always leads to a selection bias. Second, patients with pulmonary blastoma were few in number in the SEER database, which may be a strong confounding factor affecting the result of the survival analysis. Third, specific information, such as chemotherapy sequence with surgery, dose, and agent of chemotherapy are lacking in the SEER database. Therefore, the present study could not account for the effect of chemotherapy on PSC prognosis. Fourth, a number of other factors may influence the results of the present study, such as radiation regimen and the technological infrastructure of the equipment.

In conclusion, PSC is a type of poorly differentiated NSCLC composed of spindle or giant cells. Surgery is often the first choice of treatment for patients with PSC. Furthermore, radiotherapy can influence the long-term outcome in stage I--III patients with PSC who only underwent radiation therapy without surgical resection. The present population cohort study was conducted to stratify prognoses of patients with PSC despite incidence being low. Age, tumor size, TNM and pathological type were independent risk factors for the prognosis of patients with PSC. Female, married and treatment modality were independent protective factors for patients with PSC.

In summary, for patients with stage I--III who are unsuitable for surgery, radiotherapy has been demonstrated to provide a better prognosis compared with no specific treatment. In order to provide an individualized prediction method, the present study developed a novel nomogram. Taken together, the present results can aid clinical decision-making to improve prognosis.
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###### 

Demographic and clinical characteristics patients with pulmonary sarcomatoid carcinoma.

  Demographic/clinical characteristic   Cases, n (%)
  ------------------------------------- ---------------
  Age at diagnosis, years               
    \<76                                1,309 (75.97)
    ≥76                                 414 (24.03)
  Sex                                   
    Male                                1,032 (59.90)
    Female                              691 (40.10)
  Ethnicity                             
    White                               1,375 (79.80)
    Black                               239 (13.87)
    Others                              109 (6.33)
  Marital status                        
    Married                             777 (45.10)
    Unmarried                           946 (54.90)
  Laterality                            
    Left-origin of primary              739 (42.89)
    Right-origin of primary             964 (55.95)
    Bilateral, single primary           20 (1.16)
  Primary site                          
    Main bronchus                       53 (3.08)
    Upper lobe                          972 (56.41)
    Middle lobe                         89 (5.17)
    Lower lobe                          469 (27.22)
    Overlapping lesion                  42 (2.44)
    Lung, NOS                           98 (5.69)
  Pathological Type                     
    Giant cell carcinoma                535 (31.05)
    Spindle cell carcinoma              445 (25.83)
    Pleomorphic carcinoma               403 (23.39)
    Carcinosarcoma                      288 (16.72)
    Pulmonary blastoma                  52 (3.02)
  Differentiation, grade                
    I                                   20 (1.16)
    II                                  14 (0.81)
    III                                 627 (36.39)
    IV                                  332 (19.27)
    ND                                  730 (42.37)
  Tumor size, mm                        
    \<56                                923 (53.57)
    ≥56                                 800 (46.43)
  TNM                                   
    I                                   318 (18.46)
    II                                  175 (10.16)
    III                                 427 (24.78)
    IV                                  665 (38.60)
    ND                                  138 (8.01)
  Surgery                               
    No                                  940 (54.56)
    Yes                                 776 (45.04)
    ND                                  7 (0.41)
  Radiation                             
    No                                  1,038 (60.24)
    Yes                                 685 (39.76)
  Chemotherapy                          
    No                                  1,080 (62.68)
    Yes                                 643 (37.32)

ND, not determined; TNM, Tumor-Node-Metastasis; NOS, not otherwise specified.

###### 

Univariate and multivariate Cox proportional hazard analyses of the clinical characteristics for overall survival of patients with pulmonary sarcomatoid carcinoma.

                             Univariate analysis   Multivariate analysis                                       
  -------------------------- --------------------- ----------------------- --------- ---------- -------------- ---------
  Age at diagnosis, years                                                                                      
    \<76                     1 (Ref.)                                      --        1 (Ref.)                  --
    ≥76                      1.531                 1.351--1.735            \<0.001   1.440      1.265--1.639   \<0.001
  Sex                                                                                                          
    Male                     1 (Ref.)                                      --        1 (Ref.)                  --
    Female                   0.821                 0.734--0.919              0.001   0.863      0.768--0.968     0.012
  Marital status                                                                                               
    Unmarried                1 (Ref.)                                      --        1 (Ref.)                  --
    Married                  0.850                 0.762--0.949              0.004   0.869      0.776--0.974     0.016
  Pathological Type                                                                                            
    Pulmonary blastoma       1 (Ref.)                                      --        1 (Ref.)                  --
    Pleomorphic carcinoma    2.317                 1.451--3.699            \<0.001   2.043      1.269--3.291     0.003
    Spindle cell carcinoma   3.315                 2.083--5.275            \<0.001   2.210      1.373--3.557     0.001
    Carcinosarcoma           2.823                 1.752--4.547            \<0.001   2.634      1.623--4.276   \<0.001
    Giant cell carcinoma     3.638                 2.291--5.777            \<0.001   2.704      1.684--4.341   \<0.001
  Differentiation                                                                                                0.190
    I                        1 (Ref.)                                      --                                  
    II                       2.776                 1.127--6.836              0.026                             
    III                      3.038                 1.569--5.884              0.001                             
    IV                       3.621                 1.861--7.046            \<0.001                             
    Unknown                  3.785                 1.956--7.324            \<0.001                             
  Tumor size, mm                                                                                               
    \<56                     1 (Ref.)                                      --        1 (Ref)                   --
    ≥56                      1.574                 1.409--1.757            \<0.001   1.292      1.152--1.449   \<0.001
  TNM                                                                                                          
    I                        1 (Ref.)                                      --        1 (Ref.)                  --
    II                       1.416                 1.137--1.764              0.002   1.335      1.067--1.670     0.011
    III                      2.044                 1.729--2.417            \<0.001   1.593      1.320--1.923   \<0.001
    IV                       4.874                 4.140--5.739            \<0.001   2.947      2.413--3.600   \<0.001
  Treatment modality                                                                                           
    Only Surgery             0.203                 0.174--0.237            \<0.001   0.407      0.336--0.494   \<0.001
    Surgery plus RT          0.292                 0.242--0.353            \<0.001   0.406      0.332--0.497   \<0.001
    Only RT                  0.644                 0.558--0.743            \<0.001   0.672      0.580--0.778   \<0.001
    No special treatment     1 (Ref.)                                      --        1 (Ref.)                  --

CI, confidence interval; HR, hazard ratio; TNM, Tumor-Node-Metastasis; RT, radiotherapy; Ref., reference.

[^1]: Contributed equally
